Popular Research Topics by Year

• acquired resistance
• adenocarcinoma
• adjuvant
• adult
• advanced cancer
• aged
• article
• cancer chemotherapy
• cancer immunotherapy
• cancer staging
• cancer surgery
• chemoradiotherapy
• female
• human
• immunotherapy
• lung adenocarcinoma
• male
• neoadjuvant
• neoadjuvant therapy
• non small cell lung cancer
• nsclc
• overall survival
• pathologic response
• pd-1
• priority journal

• 1st-line treatment
• adenocarcinomas
• adenosquamous carcinoma
• adjuvant chemotherapy
• adjvuant immunotherapy
• adrenal metastases
• adult
• aged
• article
• bronchus injury
• cabozantinib
• cancer
• cancer adjuvant therapy
• cancer patient
• cancer staging
• cell lung-cancer
• cell-free dna
• chemotherapy
• clinical article
• computer assisted tomography
• definitive radiotherapy
• neoadjuvant
• neoadjuvant chemotherapy
• nsclc
• open-label

• aged
• article
• cancer immunotherapy
• cancer staging
• carboplatin
• chemoradiotherapy
• chemotherapy
• cisplatin
• computer assisted tomography
• concurrent chemoradiation
• drug efficacy
• drug megadose
• durvalumab
• female
• human
• ipilimumab
• lung cancer
• lung-cancer
• major clinical study
• male
• molecularly targeted therapy
• multiple cycle treatment
• nivolumab
• non small cell lung cancer
• priority journal

• adjuvant
• adjuvant therapy
• adult
• aged
• aging
• alk fusion
• article
• atezolizumab
• brg1 protein
• cancer chemotherapy
• cancer radiotherapy
• cancer staging
• cardiac toxicity
• cohort analysis
• controlled study
• female
• heart dose
• human
• major clinical study
• male
• neoadjuvant
• non small cell lung cancer
• osimertinib
• pd-l1
• priority journal

• antineoplastic agent
• antineoplastic combined chemotherapy protocols
• article
• biomarkers, tumor
• cancer staging
• carcinoma, non-small-cell lung
• circulating tumor dna
• clinical trial
• epidermal growth factor receptor
• genetics
• high throughput sequencing
• human
• humans
• immune checkpoint inhibitors
• immunocompetent cell
• lung neoplasms
• lung tumor
• mouse
• mutation
• neoadjuvant therapy
• non small cell lung cancer
• pathology
• protein expression
• treatment response
• tumor marker

• adult
• aged
• b7-h1 antigen
• cancer staging
• carcinoma, non-small-cell lung
• chemotherapy
• clinical trial
• cohort analysis
• controlled study
• durvalumab
• female
• genetics
• human
• humans
• immune checkpoint inhibitors
• lung neoplasms
• lung tumor
• male
• neoadjuvant therapy
• non small cell lung cancer
• pathology
• programmed death 1 ligand 1
• retrospective studies
• retrospective study
• small cell lung cancer

• adult
• aged
• antineoplastic agent
• article
• cancer chemotherapy
• cancer immunotherapy
• cancer staging
• carcinoma, non-small-cell lung
• chemotherapy
• cohort analysis
• controlled study
• event free survival
• female
• human
• humans
• immunotherapy
• lung neoplasms
• lung tumor
• major clinical study
• male
• neoadjuvant therapy
• non small cell lung cancer
• overall survival
• prospective study
• treatment outcome

• adenocarcinoma of lung
• adult
• advanced cancer
• aged
• amp-activated protein kinase kinases
• article
• cancer control
• cancer patient
• cancer recurrence
• clinical feature
• clinical outcome
• cohort analysis
• female
• human
• humans
• lung cancer
• lung neoplasms
• lung tumor
• major clinical study
• male
• middle aged
• non small cell lung cancer
• overall survival
• pathology
• retrospective study